Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Beats Expectations By $0.06 EPS

Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports.

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded up $0.19 during mid-day trading on Thursday, reaching $4.01. The stock had a trading volume of 617,811 shares, compared to its average volume of 1,446,828. Compass Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $4.86. The stock’s 50-day simple moving average is $3.75 and its 200-day simple moving average is $2.95. The firm has a market capitalization of $554.64 million, a PE ratio of -8.90 and a beta of 1.48.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CMPX. Adage Capital Partners GP L.L.C. lifted its holdings in Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after acquiring an additional 449,868 shares during the period. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the second quarter valued at $84,000. Marex Group plc bought a new stake in shares of Compass Therapeutics in the second quarter valued at $61,000. Invesco Ltd. raised its stake in shares of Compass Therapeutics by 58.1% in the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after buying an additional 21,578 shares during the period. Finally, Strs Ohio bought a new stake in shares of Compass Therapeutics in the first quarter valued at $34,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CMPX. Guggenheim increased their price target on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. Lifesci Capital started coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price objective on the stock. Compass Point set a $10.00 price objective on Compass Therapeutics in a report on Monday, October 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $12.90.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.